References
- World Health Organization. The Asia-Pacific Perspective: Redefining Obesity and Is Treatment. Sydney: Health Communications Australia;2000.
- Korea Disease Control and Prevention Agency. Korea Health Statistics 2019: Korea National Health and Nutrition Examination Survey (KNHANES VIII-1). Cheongju: Korea Disease Control and Prevention Agency;2020.
- Kosis.kr [homepage on the Internet]. Korea: Ministry of Food and Drug Safety [updated 2021 July 23; cited 2022 Feb 18]. Available from: https://kosis.kr/statHtml/statHtml.do?orgId=145&tblId=DT_145013_044&conn_path=I2.
- Seo MH, Kim YH, Han K, Jung JH, Park YG, Lee SS, et al. Prevalence of obesity and incidence of obesity-related comorbidities in Koreans based on National Health Insurance Service health checkup data 2006-2015. J Obes Metab Syndr 2018;27:46-52. https://doi.org/10.7570/jomes.2018.27.1.46
- Seo MH, Lee WY, Kim SS, Kang JH, Kang JH, Kim KK, et al. 2018 Korean Society for the study of obesity guideline for the management of obesity in Korea. J Obes Metab Syndr 2019;28:40-45. https://doi.org/10.7570/jomes.2019.28.1.40
- Bray GA, Heisel WE, Afshin A, Jensen MD, Dietz WH, Long M, et al. The science of obesity management: an endocrine society scientific statement. Endocr Rev 2018;39:79-132. https://doi.org/10.1210/er.2017-00253
- Jo SJ, Lee HK, Park BJ, Kang HC, Lee SY, Jo JB. A rapid systematic review on adverse effects of psychostimulant appetite suppressants: focusing on dependence and psychosis. J Korean Academy of Addiction Psychiatry 2021;25:45-57. https://doi.org/10.37122/kaap.2021.25.2.45
- Rothman RB, Baumann MH. Appetite suppressants, cardiac valve disease and combination pharmacotherapy. Am J Ther 2009;16:354-364. https://doi.org/10.1097/MJT.0b013e31817fde95
- Kim KK. Mechanisms of action and clinical applications of antiobesity drugs currently available in Korea. J Korean Med Assoc 2019;62:588-597. https://doi.org/10.5124/jkma.2019.62.11.588
- Bramness JG, Gundersen OH, Guterstam J, Rognli EB, Konstenius M, Loberg EM, et al. Amphetamine-induced psychosis--a separate diagnostic entity or primary psychosis triggered in the vulnerable? BMC Psychiatry 2012;12:221.
- Rubin RT. Acute psychotic reaction following ingestion of phentermine. Am J Psychiatry 1964;120:1124-1125. https://doi.org/10.1176/ajp.120.11.1124
- Homola J, Hieber R. Combination of venlafaxine and phentermine/topiramate induced psychosis: a case report. Ment Health Clin 2018;8:95-99. https://doi.org/10.9740/mhc.2018.03.095
- Alexander J, Cheng YH, Choudhary J, Dinesh A. Phentermine (Duromine) precipitated psychosis. Aust N Z J Psychiatry 2011;45:684-685.
- Lee SH, Liu CY, Yang YY. Schizophreniform-like psychotic disorder induced by phentermine: a case report. Zhonghua Yi Xue Za Zhi (Taipei) 1998;61:44-47.
- Cleare AJ. Phentermine, psychosis, and family history. J Clin Psychopharmacol 1996;16:470-471. https://doi.org/10.1097/00004714-199612000-00020
- Devan GS. Phentermine and psychosis. Br J Psychiatry 1990;156:442-443. https://doi.org/10.1192/bjp.156.3.442
- Hoffman BF. Diet pill psychosis: follow-up after 6 years. Can Med Assoc J 1983;129:1077-1078.
- Hoffman BF. Diet pill psychosis. Can Med Assoc J 1977;116:351-355.
- Raison CL, Klein HM. Psychotic mania associated with fenfluramine and phentermine use. Am J Psychiatry 1997;154:711.
- Bagri S, Reddy G. Delirium with manic symptoms induced by diet pills. J Clin Psychiatry 1998;59:83.
- Zimmer JE, Gregory RJ. Bipolar depression associated with fenfluramine and phentermine. J Clin Psychiatry 1998;59:383-384. https://doi.org/10.4088/JCP.v59n0707e
- Kim SH, Ahn DH, Yoo TH. A case of organic hallucinous following phendimetrazine(Fringar@) abuse. J Korean Neuropsychiatr Assoc 1992;31:1119-1122.
- Lee JM, Lee KU, Jhoo JH, Park JI. Two cases of psychotic disorder following phendimetrazine use. Korean J Psychopharmacol 2010;21:95-98.
- Yun JA, Park WR, Yu JC, Choi KS. A case of phendimetrazine induced-psychotic disorder and dependence. J Korean Neuropsychiatr Assoc 2013;52:402-405. https://doi.org/10.4306/jknpa.2013.52.5.402
- Kwak SY, Youn TY, Lee NY, Chung IW, Kim SH. Psychotic disorder induced by appetite suppressants, phentermine or phendimetrazine: a case series study. Korean J Biol Psychiatry 2017;24:134-141.
- Jo HS, Wang SM, Kim JJ. Recurrent psychosis after phentermine administration in a young female: a case report. Clin Psychopharmacol Neurosci 2019;17:130-133. https://doi.org/10.9758/cpn.2019.17.1.130
- Starzer MSK, Nordentoft M, Hjorthoj C. Rates and predictors of conversion to schizophrenia or bipolar disorder following substance-induced psychosis. Am J Psychiatry 2018;175:343-350. https://doi.org/10.1176/appi.ajp.2017.17020223
- Sadock BJ, Sadock VA, Ruiz P. Kaplan & Sadock's Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry. 11th ed. Philadelphia: Lippincott Williams & Wilkins;2015.
- Baumann MH, Ayestas MA, Dersch CM, Brockington A, Rice KC, Rothman RB. Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: therapeutic implications. Synapse 2000;36:102-113. https://doi.org/10.1002/(SICI)1098-2396(200005)36:2<102::AID-SYN3>3.0.CO;2-#
- Solis E Jr, Suyama JA, Lazenka MF, DeFelice LJ, Negus SS, Blough BE, et al. Dissociable effects of the prodrug phendimetrazine and its metabolite phenmetrazine at dopamine transporters. Sci Rep 2016;6:31385.
- An H, Sohn H, Chung S. Phentermine, sibutramine and affective disorders. Clin Psychopharmacol Neurosci 2013;11:7-12. https://doi.org/10.9758/cpn.2013.11.1.7
- Niemi-Pynttari JA, Sund R, Putkonen H, Vorma H, Wahlbeck K, Pirkola SP. Substance-induced psychoses converting into schizophrenia: a register-based study of 18,478 Finnish inpatient cases. J Clin Psychiatry 2013;74:e94-e99. https://doi.org/10.4088/JCP.12m07822
- Chen WL, Hsieh CH, Chang HT, Hung CC, Chan CH. The epidemiology and progression time from transient to permanent psychiatric disorders of substance-induced psychosis in Taiwan. Addict Behav 2015;47:1-4. https://doi.org/10.1016/j.addbeh.2015.02.013